Skip to main content
Erschienen in: Respiratory Research 1/2014

Open Access 01.12.2014 | Research

Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease

verfasst von: Kohei Hasegawa, Yusuke Tsugawa, Chu-Lin Tsai, David FM Brown, Carlos A Camargo Jr

Erschienen in: Respiratory Research | Ausgabe 1/2014

Abstract

Background

Little is known about patients who frequently visit the emergency department (ED) for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). We aimed to quantify the proportion and characteristics of patients with frequent ED visits for AECOPD and associated healthcare utilization.

Methods

We conducted a retrospective cohort study of adults aged ≥40 years with at least one ED visit for AECOPD between 2010 and 2011, derived from population-based all-payer data of State ED and Inpatient Databases for two large and diverse states: California and Florida. Outcome measures were frequency of ED visits for AECOPD, 30-day ED revisits, subsequent hospitalizations, near-fatal events (AECOPD involving mechanical ventilation), and charges for both ED and inpatient services (available only for Florida) during the year after the first ED visit.

Results

The analytic cohort comprised 98,280 unique patients with 154,736 ED visits for AECOPD. During the 1-year period, 29.4% (95% CI, 29.1%-29.7%) of the patients had two or more (frequent) visits, accounting for 55.2% (95% CI, 54.9%-55.4%) of all ED visits for AECOPD. In the multivariable model, significant predictors of frequent ED visits were age 55–74 years (vs. 40–54 years), male sex, non-Hispanic white or black race, Medicaid insurance (vs. private), and lower median household income (all P < 0.001). At the visit-level, 12.3% of ED visits for AECOPD were 30-day revisit events (95% CI, 12.1%-12.4%). Additionally, 62.8% of ED visits for AECOPD (95% CI, 62.6%-63.0%) resulted in a hospitalization; patients with frequent ED visits comprised 55.5% (95% CI, 55.2%-55.8%) of all hospitalizations. Furthermore, 7.3% (95% CI, 7.3%-7.5%) of ED visits for AECOPD led to a near-fatal event; patients with frequent ED visits accounted for 64.4% (95% CI, 63.5%-65.3%) of all near-fatal events. Total charges for AECOPD were $1.94 billion (95% CI, $1.90-1.97 billion) in Florida; patients with frequent ED visits accounted for $1.07 billion (95% CI, $1.04-1.09 billion).

Conclusions

In this large cohort study, we found that 29% had frequent ED visits for AECOPD and that lower socioeconomic status was significantly associated with a higher frequency of ED visits. Individuals with frequent ED visits for AECOPD accounted for a substantial amount of healthcare utilization and financial burden.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1465-9921-15-40) contains supplementary material, which is available to authorized users.

Competing interests

Dr. Camargo has provided consultation for AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer, and received research grants from AstraZeneca and Novartis. The other authors have no financial relationships relevant to this article to disclose.

Authors’ contributions

Conception and design: KH, YT, and CC; Analysis and interpretation: KH, YT, CT, DB, and CC; Drafting the manuscript for important intellectual content: KH, YT, CT, DB, and CC. All authors read and approved the final manuscript.
Abkürzungen
AECOPD
Acute exacerbation of chronic obstructive pulmonary disease
AHRQ
Agency for Healthcare Research and Quality
COPD
Chronic obstructive pulmonary disease
ED
Emergency department
HCUP
Healthcare Cost and Utilization Project
ICD-9-CM
International Classification of Diseases, Ninth Revision, Clinical Modification
SEDD
State Emergency Department Databases
SID
State Inpatient Databases.

Background

Chronic obstructive pulmonary disease (COPD) is a serious public health problem in the US. Acute exacerbations of COPD (AECOPD) were responsible for approximately 1.5 million emergency department (ED) visits and 700,000 hospitalizations in 2010 [1]. Furthermore, acute exacerbations accelerate decline in lung function, reduce patient’s quality of life, and increase health care use [24]. Indeed, exacerbation management was estimated to account for up to 70% of total direct costs of COPD management [5, 6].
In this context, the US government recently identified reducing ED visits for AECOPD as a national objective in Healthy People 2020[7]. To develop and implement preventive strategies effectively, identifying patients at risk for future exacerbations is critical. Prior studies have identified risk factors associated with frequent exacerbations (2 or more exacerbations in a year), such as a history of previous exacerbations, disease severity, poor disease-specific health status, gastroesophageal reflex, and non-private insurance status [811]. However, these studies were conducted within limited populations (e.g., patients in urban academic centers, and population in one state), thereby limiting generalizability of their results. Despite a substantial burden of COPD-related ED visits in an already stressed healthcare system, there have been no large cohort studies to characterize this high-risk patient population in the US.
To address these knowledge gaps, using large all-payer databases from two geographically dispersed states, we sought to quantify the proportion and characteristics of patients with frequent ED visits for AECOPD and associated healthcare burden, including rates of 30-day ED revisit, hospitalizations, near-fatal events, and hospital charges. A better understanding of these important issues in ED patients with AECOPD may inform potential strategies to improve their COPD management and reduce healthcare spending.

Methods

Study design and setting

We conducted a retrospective cohort study using data from the Healthcare Cost and Utilization Project (HCUP) State Emergency Department Databases (SEDD) and State Inpatient Databases (SID). The SEDD includes all treat-and-release and transfer ED visits from short-term, acute-care, nonfederal, community hospitals in participating states. The SID includes all inpatient discharges from short-term, acute-care, nonfederal, general, and other specialty hospitals in participating states, including those admitted from the ED. Taken together, we identified all ED visits regardless of disposition and contained information on short-term outcomes for patients admitted through the ED. Additional details of the SEDD and SID can be found elsewhere [12, 13].
In this study, we used the data from California and Florida SEDD and SID in 2010 and 2011. These two states were selected for their geographic distribution, high data quality, and mainly because their databases included unique encrypted patient-level identifiers that enable follow-up of specific patients across years. The institutional review board of our hospital waived review of this study.

Study population

We identified all adults aged 40 years or older with at least one ED visit for AECOPD in 2010, by using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for: 1) chronic bronchitis (491.xx), emphysema (492.xx), or chronic airway obstruction (496.xx) in the primary diagnosis field; or 2) acute respiratory failure (518.81, 518.82, or 518.84) listed in the primary diagnosis field and COPD listed as the secondary diagnosis (491.xx, 492.xx, or 496.xx). To minimize the potential misclassification of acute bronchitis as COPD, we did not include bronchitis not specified (490.xx). Likewise, we excluded patients younger than 40 years because they are less likely to have COPD [5]. We also excluded out-of-state residents, and patients who died at the first ED visit or hospitalization during the study period.

Covariates

The databases contain information on patient characteristics, including demographics (age, sex, and race/ethnicity), primary insurance type, household income, urban–rural status, ICD-9-CM diagnosis, and patient comorbidities. The SEDD database also includes ED disposition. The patient characteristics at the first visit were used for the primary analysis. Primary insurance types were categorized into Medicaid, Medicare, private sources, self-pay, and other. Quartile classifications of estimated median household income of residents in the patient’s ZIP Code were examined. These values were derived from the annual ZIP Code-demographic data and included in the SEDD and SID databases. Because these estimate are updated annually, the values ranges for the categories vary by year [12, 13]. Urban–rural status of the patient residence was defined according to the National Center for Health Statistics [14]. To adjust for potential confounding by patient-mix, 29 Elixhauser comorbidity measures were derived based on the ICD-9-CM codes using the Agency for Healthcare Research and Quality (AHRQ) Comorbidity Software [15]. This risk adjustment tool has been derived and validated extensively [16].

Outcome measures

The primary outcome measure was the frequency of ED visits for AECOPD in a given year for each patient. The patient’s first ED visit in 2010 was identified as the index ED visit. Each patient was then followed for 365 days after the index visit; then, the total number of ED visits for each patient was summated during the follow-up period, including the index visit.
Other outcome measures of interest were 30-day ED revisits, hospitalizations, near-fatal events, and charges for both ED and inpatient services. Thirty-day ED revisit was defined as an ED visit for AECOPD within 30 days of the previous ED or hospital discharge. Hospitalization was defined as a hospital admission for AECOPD from ED during the year after the index visit. Near-fatal event was defined as an ED visit or hospitalization for AECOPD involving noninvasive or invasive mechanical ventilation [17]; the use of mechanical ventilation was identified using the HCUP Clinical Classifications Software code 216. Charges reflect the total facility fees aggregated for a given individual; they are not available in the California datasets. All charges were converted to 2011 US dollars using the medical component of the Consumer Price Index [18].

Statistical analysis

For the purpose of this analysis, we categorized patients into three ED utilization groups according to the distribution of COPD-related ED visits and previous literature [8]: one ED visit (i.e., index visit only), two ED visits, and three or more ED visits within one year. First, we tested for unadjusted associations between patient-level variables and the frequency of ED visits for AECOPD using chi-square test or Kruskal-Wallis test, as appropriate. The patient-level covariates at the first visit were used for the analysis. Then, we fit multinomial logistic regression models to examine associations between patient-level variables and frequency of ED visits, with one ED visit group as the reference, adjusting for patient-mix using Elixhauser comorbidity measures.
Additionally, we calculated the rate of 30-day ED revisits, hospitalizations, and near-fatal events according to the ED visit utilization. The rates were defined as the total number of respective outcomes within a year of the index ED visit divided by the total number of ED visits for AECOPD. Then, we examined associations between the frequency of ED visits and these rates. We also performed linear regression at the patient-level to examine a linear association between the frequency of ED visits and charges.
In sensitivity analyses, to assess the consistency of associations between the frequency of ED visits and each outcome, we stratified the analysis by state, and included data from Nebraska. Data from Nebraska was not used for the primary analysis as they did not include race/ethnicity. Additionally, to further investigate predictors of a higher frequency of ED visits, a negative binomial regression model with quasi-likelihood estimation was used [19]. This model has advantages that there is no need to define an arbitrary cutoff point and that this model appropriately accounts for statistical over-dispersion [20, 21]. All analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC) and results were presented with 95% confidence interval (CI), when appropriate. A two-sided P value <0.05 was considered statistically significant.

Results

All ED visits for AECOPD made by patients aged 40 years or older in 2010 and 2011 (n = 294,678) were identified in the California and Florida databases. From this population, we sequentially excluded ED visits occurred >365 days after the index visit (n = 23,485), those made by patients who had no ED visits in 2010 (n = 104,510), and those without a valid encrypted patient identifier (n = 6,583). We also excluded ED visits made by patients with out-of-state residence (n = 4,331) or who died at the index ED visit (n = 1033). After these exclusions, the analytic cohort comprised 98,280 unique patients with 154,736 ED visits for AECOPD.

ED visits for AECOPD

Among this analytic cohort, 69,398 patients (70.6%; 95% CI, 70.3%-70.9%) reported one ED visit during the 1-year study period, while 28,882 patients (29.4%; 95% CI, 29.1%-29.7%) had two or more (frequent) visits. Figure 1 demonstrates the number of patients and ED visits for AECOPD during the study period by ED visit frequency. Patients with frequent visits accounted for 55.2% (95% CI, 54.9%-55.4%) of all ED visits for AECOPD.
In the sensitivity analysis, the distribution of ED visit frequency was similar across California and Florida (Figure 2), with the comparable findings in Nebraska. For example, 29.7% of patients in California had frequent ED visits and accounted for 55.9% (95% CI, 55.5%-56,2%) of all ED visits; 29.1% patients in Florida had frequent visits and accounted for 54.5% (95% CI, 54.1%-54.8%) of all ED visits; 29.6% patients in Nebraska had frequent ED visits and accounted for 54.0% (95% CI, 52.5%-55.5%) of all ED visits.

Patient characteristics

Patient demographics, socioeconomic factors, and comorbidities differed across the ED visit frequency groups (Table 1). Compared to patients with one ED visit, patients with a higher frequency of ED visits were more likely to be age 55–74 years, male sex, and non-Hispanic black race. Similarly, several markers of socioeconomic status, such as Medicaid insurance and lower median household income, were associated with a higher frequency of ED visits.
Table 1
Demographic and Comorbidities of Patients with Chronic Obstructive Pulmonary Disease (COPD), according to the number of COPD-related emergency department visits in one year
 
1 ED visit
2 ED visits
≥ 3 ED visits
 
Variables*
(n = 69,398)
(n = 17,005)
(n = 11,877)
P value
Age (y), median (IQR)
69 (58–79)
69 (59–78)
67 (58–76)
<0.001
 40-54 years
11,922 (17)
2595 (15)
2010 (17)
<0.001
 55-64 years
14,807 (21)
3815 (22)
3288 (28)
 
 65-74 years
17,049 (25)
4575 (27)
3287 (28)
 
 75-84 years
16,788 (24)
4160 (24)
2441 (21)
 
 85 years and older
8832 (13)
1860 (11)
851 (7)
 
Male sex
30,633 (44)
7632 (45)
5527 (47)
<0.001
Race/ethnicity
   
<0.001
 Non-hispanic white
51,557 (74)
12,746 (75)
8713 (73)
 
 Non-hispanic black
6349 (9)
1702 (10)
1577 (13)
 
 Hispanic
7715 (11)
1732 (10)
1068 (9)
 
 Other
2484 (4)
569 (3)
337 (3)
 
 Missing
1303 (2)
256 (2)
182 (2)
 
Insurance status
    
 Medicare
46,174 (67)
11,829 (70)
7793 (66)
<0.001
 Medicaid
8092 (12)
2417 (14)
2413 (20)
 
 Private
7931 (11)
1299 (8)
729 (6)
 
 Self-pay
4322 (6)
71 (4)
431 (4)
 
 Other
2870 (4)
699 (4)
508 (4)
 
Quartiles for median household income of patient’s ZIP code
 
<0.001
 1 (lowest)
22,390 (32)
5749 (34)
4415 (37)
 
 2
19,307 (28)
4800 (28)
3325 (28)
 
 3
15,904 (23)
3797 (22)
2497 (21)
 
 4 (highest)
10,524 (15)
2308 (14)
1372 (12)
 
 Missing
1273 (2)
351 (2)
268 (2)
 
Patient residence
   
<0.001
 Counties of ≥ 1 million population
42,303 (61)
10,245 (60)
7123 (60)
 
 Counties of 250,000-999,999 population
17,379 (25)
4319 (25)
2983 (25)
 
 Counties of 50,000-249,999 population
4103 (6)
1053 (6)
750 (6)
 
 Counties of < 50,000 population
5590 (8)
1335 (8)
956 (8)
 
State
   
0.02
 California
33,741 (49)
8297 (49)
5942 (50)
 
 Florida
35,657 (51)
8708 (51)
5935 (50)
 
 Any comorbidities
54,633 (79)
13,888 (82)
9644 (81)
<0.001
Selected comorbidities§
    
 Congestive heart failure
13,607 (20)
3831 (23)
2708 (23)
<0.001
 Pulmonary circulation disorders
674 (1)
269 (2)
198 (2)
<0.001
 Diabetes, uncomplicated
14,813 (21)
3931 (23)
2939 (25)
<0.001
 Obesity
7195 (10)
1935 (11)
1437 (12)
<0.001
 Depression
6357 (9)
1886 (11)
1479 (12)
<0.001
 Psychoses
3233 (5)
1001 (6)
847 (7)
<0.001
 Drug abuse
1430 (2)
458 (3)
528 (4)
<0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, IQR interquartile range.
*Data were expressed as n (%) unless otherwise indicated.
Unadjusted comparisons were tested using chi-square test unless otherwise indicated.
Unadjusted comparison was tested using Kruskal-Wallis test.
§Comorbidity was defined as at least 1 Elixhauser comorbidity measure.
In a multinomial logistic regression model (Table 2), these patient characteristics remained significant as independent predictors of a higher frequency of ED visits across the frequency groups. For example, non-Hispanic white race (OR, 1.32; 95% CI, 1.23-1.41), non-Hispanic black race (OR, 1.59; 95% CI, 1.45-1.73), Medicaid insurance (OR, 2.92; 95% CI, 2.66-3.20), and lowest quartile for household income (OR, 1.29; 95%CI, 1.21-1.38) were independently associated with three or more ED visits within one year. In addition, certain comorbidities such as congestive heart failure, pulmonary circulation disorders, depression, and psychoses were associated with a higher frequency of ED visits. In the sensitivity analyses, these associations remained statistically significant with stratification by state and the use of negative binomial regression model (Tables 3 and 4).
Table 2
Multinomial regression models for factors associated with frequent emergency department visits for acute exacerbation of chronic obstructive pulmonary disease
 
2 (vs. 1) ED visits
≥ 3 (vs. 1) ED visits
Variables
Odds ratio (95% CI)
P value
Odds ratio (95% CI)
P value
Age, y
 
<0.001
 
<0.001
 40-54 years
1 [reference]
 
1 [reference]
 
 55-64 years
1.15 (1.09-1.22)
<0.001
1.31 (1.23-1.39)
<0.001
 65-74 years
1.14 (1.07-1.22)
<0.001
1.11 (1.03-1.20)
0.006
 75-84 years
1.05 (0.98-1.12)
0.10
0.86 (0.79-0.93)
<0.001
 85 years and older
0.90 (0.83-0.97)
0.03
0.58 (0.52-0.64)
<0.001
Male sex
1.04 (1.00-1.08)
0.048
1.12 (1.07-1.17)
<0.001
Race/ethnicity
    
 Non-hispanic white
1.15 (1.08-1.21)
<0.001
1.32 (1.23-1.41)
<0.001
 Non-hispanic black
1.17 (1.09-1.27)
<0.001
1.59 (1.46-1.73)
<0.001
 Hispanic
1 [reference]
 
1 [reference]
 
 Other
1.07 (0.96-1.19)
0.29
1.07 (0.96-1.19)
0.33
Insurance status
    
 Medicare
1.58 (1.47-1.69)
<0.001
2.10 (1.92-2.29)
<0.001
 Medicaid
1.77 (1.64-1.92)
<0.001
2.92 (2.66-3.20)
<0.001
 Private
1 [reference]
 
1 [reference]
 
 Self-pay
1.11 (1.00-1.23)
0.046
1.05 (0.92-1.20)
0.45
 Other
1.46 (1.32-1.62)
<0.001
1.78 (1.57-2.02)
<0.001
Quartiles for median household income of patient’s ZIP code
  
 1 (lowest)
1.13 (1.07-1.20)
<0.001
1.29 (1.21-1.38)
<0.001
 2
1.11 (1.05-1.18)
<0.001
1.22 (1.14-1.31)
<0.001
 3
1.08 (1.01-1.14)
0.01
1.14 (1.06-1.22)
<0.001
 4 (highest)
1 [reference]
 
1 [reference]
 
Patient residence
    
 Counties of ≥ 1 million population
1.07 (1.00-1.15)
0.06
1.09 (1.01-1.18)
0.03
 Counties of 250,000-999,999 population
1.07 (1.00-1.15)
0.07
1.09 (1.00-1.18)
0.06
 Counties of 50,000-249,999 population
1.09 (1.00-1.20)
0.06
1.10 (0.99-1.23)
0.09
 Counties of < 50,000 population
1 [reference]
 
1 [reference]
 
State
    
 California
1.01 (0.98-1.05)
0.44
1.06 (1.02-1.11)
0.006
 Florida
1 [reference]
 
1 [reference]
 
Selected comorbidities*
    
 Congestive heart failure
1.17 (1.11-1.22)
<0.001
1.24 (1.17-1.30)
<0.001
 Pulmonary circulation disorders
1.41 (1.22-1.64)
<0.001
1.39 (1.17-1.64)
<0.001
 Diabetes, uncomplicated
1.05 (1.01-1.10)
0.02
1.13 (1.07-1.19)
<0.001
 Obesity
0.99 (0.94-1.05)
0.79
0.97 (0.91-1.03)
0.31
 Depression
1.21 (1.14-1.28)
<0.001
1.38 (1.30-1.47)
<0.001
 Psychoses
1.17 (1.09-1.27)
<0.001
1.27 (1.17-1.38)
<0.001
 Drug abuse
1.22 (1.09-1.37)
<0.001
1.66 (1.48-1.85)
<0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, CI confidence interval.
Bold results are statistically significant.
*Non-significant Elixhauser comorbidity measures across the frequency groups included peripheral vascular disease, hypertension, neurological disorders, diabetes with complications, liver disease, peptic ulcer disease, acquired immunodeficiency syndrome, lymphoma, solid tumor without metastasis, coagulopathy, fluid and electrolyte disorders, anemia, and alcohol abuse.
Table 3
Multinomial regression models for factors associated with frequent emergency department visits for acute exacerbation of chronic obstructive pulmonary disease, stratified by state
 
California
Florida
 
2 (vs. 1) ED visits
≥ 3 (vs. 1) ED visits
2 (vs. 1) ED visits
≥ 3 (vs. 1) ED visits
Variables
Odds ratio (95% CI)
P value
Odds ratio (95% CI)
P value
Odds ratio (95% CI)
P value
Odds ratio (95% CI)
P value
Age, y
        
 40-54 years
1 [reference]
 
1 [reference]
 
1 [reference]
 
1 [reference]
 
 55-64 years
1.20 (1.11-1.31)
<0.001
1.32 (1.21-1.45)
<0.001
1.11 (1.03-1.21)
0.008
1.28 (1.17-1.41)
<0.001
 65-74 years
1.17 (1.07-1.29)
0.001
1.16 (1.04-1.29)
0.008
1.13 (1.03-1.23)
0.01
1.05 (0.95-1.17)
0.34
 75-84 years
1.15 (1.04-1.27)
0.007
0.90 (0.80-1.01)
0.08
0.98 (0.89-1.08)
0.73
1.81 (0.73-0.91)
<0.001
 85 years and older
0.99 (0.88-1.11)
0.83
0.61 (0.53-0.70)
<0.001
0.85 (0.76-0.96)
0.007
0.54 (0.47-0.63)
<0.001
Male sex
1.05 (1.00-1.10)
0.048
1.13 (1.06-1.19)
<0.001
1.03 (0.98-1.08)
0.30
1.11 (1.05-1.18)
<0.001
Race/ethnicity
        
 Non-hispanic white
1.15 (1.06-1.25)
0.001
1.32 (1.20-1.46)
<0.001
1.13 (1.03-1.23)
0.004
1.30 (1.17-1.44)
<0.001
 Non-hispanic black
1.24 (1.11-1.38)
0.001
1.71 (1.51-1.93)
<0.001
1.12 (1.01-1.25)
0.04
1.49 (1.31-1.69)
<0.001
 Hispanic
1 [reference]
 
1 [reference]
 
1 [reference]
 
1 [reference]
 
 Other
1.23 (1.00-1.28)
0.06
1.16 (0.99-1.35)
0.06
0.85 (0.65-1.10)
0.21
0.80 (0.57-1.12)
0.20
Insurance status
        
 Medicare
1.55 (1.41-1.71)
<0.001
1.88 (1.67-2.11)
<0.001
1.63 (1.47-1.81)
<0.001
2.41 (2.11-2.75)
<0.001
 Medicaid
1.65 (1.48-1.83)
<0.001
2.58 (2.29-2.92)
<0.001
1.96 (1.75-2.20)
<0.001
3.38 (2.93-3.89)
<0.001
 Private
1 [reference]
 
1 [reference]
 
1 [reference]
 
1 [reference]
 
 Self-pay
1.10 (0.95-1.28)
0.21
1.05 (0.87-1.27)
0.62
1.13 (0.98-1.29)
0.09
1.11 (0.92-1.33)
0.29
 Other
1.34 (1.14-1.57)
<0.001
1.34 (1.10-1.62)
0.004
1.58 (1.37-1.81)
<0.001
2.25 (1.90-2.67)
<0.001
Quartiles for median household income of patient’s ZIP code
 1 (lowest)
1.24 (1.13-1.37)
<0.001
1.18 (1.09-1.28)
<0.001
1.10 (1.01-1.19)
0.03
1.22 (1.11-1.34)
<0.001
 2
1.22 (1.12-1.32)
<0.001
1.24 (1.13-1.37)
<0.001
1.03 (0.95-1.11)
0.49
1.19 (1.08-1.31)
<0.001
 3
1.12 (1.03-1.21)
0.001
1.20 (1.09-1.33)
<0.001
1.04 (0.95-1.13)
0.40
1.07 (0.97-1.19)
0.19
 4 (highest)
1 [reference]
 
1 [reference]
 
1 [reference]
 
1 [reference]
 
Patient residence
        
 Counties of ≥ 1 million population
1.00 (0.89-1.12)
0.99
0.97 (0.86-1.11)
0.69
1.10 (1.01-1.20)
0.03
1.16 (1.04-1.28)
0.005
 Counties of 250,000-999,999 population
1.06 (0.94-1.20)
0.34
1.02 (0.89-1.17)
0.78
1.07 (0.98-1.17)
0.16
1.09 (0.98-1.22)
0.10
 Counties of 50,000-249,999 population
1.01 (0.87-1.06)
0.92
1.04 (0.89-1.22)
0.65
1.16 (1.02-1.32)
0.02
1.10 (0.94-1.28)
0.23
 Counties of < 50,000 population
1 [reference]
 
1 [reference]
 
1 [reference]
 
1 [reference]
 
Selected comorbidities
        
 Congestive heart failure
1.16 (1.09-1.23)
<0.001
1.27 (1.18-1.36)
<0.001
1.18 (1.11-1.26)
<0.001
1.22 (1.13-1.31)
<0.001
 Pulmonary circulation disorders
1.51 (1.22-1.86)
<0.001
1.34 (1.04-1.73)
0.02
1.29 (1.05-1.60)
0.02
1.37 (1.09-1.73)
0.008
 Diabetes, uncomplicated
1.02 (0.96-1.09)
0.47
1.14 (1.06-1.23)
<0.001
1.08 (1.02-1.15)
0.009
1.12 (1.05-1.20)
<0.001
 Obesity
1.01 (0.92-1.10)
0.85
0.96 (0.87-1.06)
0.42
0.98 (0.91-1.06)
0.60
0.97 (0.89-1.06)
0.50
 Depression
1.22 (1.11-1.33)
<0.001
1.39 (1.26-1.54)
<0.001
1.19 (1.10-1.28)
<0.001
1.37 (1.26-1.49)
<0.001
 Psychoses
1.19 (1.07-1.32)
0.001
1.26 (1.13-1.42)
<0.001
1.16 (1.04-1.29)
0.01
1.28 (1.14-1.45)
<0.001
 Drug abuse
1.27 (1.10-1.47)
0.001
1.72 (1.49-1.97)
<0.001
1.16 (0.97-1.39)
0.10
1.55 (1.30-1.86)
<0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, CI confidence interval.
Bold results are statistically significant.
Table 4
Negative binomial regression model for factors associated with frequency of emergency department visits for acute exacerbation of chronic obstructive pulmonary disease
Variables
Risk ratio (95% CI)
P value
Age, y
  
 40-54 years
1 [reference]
 
 55-64 years
1.07 (1.06-1.09)
<0.001
 65-74 years
1.02 (1.00-1.03)
0.04
 75-84 years
0.94 (0.92-0.96)
<0.001
 85 years and older
0.86 (0.85-0.88)
<0.001
Male sex
  
Race/ethnicity
  
 Non-hispanic white
1.08 (1.06-1.09)
<0.001
 Non-hispanic black
1.15 (1.13-1.17)
<0.001
 Hispanic
1 [reference]
 
 Other
1.01 (0.98-1.03)
0.62
Insurance status
  
 Medicare
1.21 (1.19-1.23)
<0.001
 Medicaid
1.34 (1.32-1.36)
<0.001
 Private
1 [reference]
 
 Self-pay
1.01 (0.99-1.03)
0.45
 Other
1.13 (1.10-1.16)
<0.001
Quartiles for median household income of patient’s ZIP code
 1 (lowest)
1.06 (1.05-1.08)
<0.001
 2
1.05 (1.03-1.06)
<0.001
 3
1.03 (1.01-1.04)
<0.001
 4 (highest)
1 [reference]
 
Patient residence
  
 Counties of ≥ 1 million population
1.03 (1.01-1.05)
<0.001
 Counties of 250,000-999,999 population
1.04 (1.02-1.05)
<0.001
 Counties of 50,000-249,999 population
1.03 (1.01-1.06)
0.007
 Counties of < 50,000 population
1 [reference]
 
State
  
 California
1.02 (1.02-1.03)
<0.001
 Florida
1 [reference]
 
Selected comorbidities
  
 Congestive heart failure
1.05 (1.04-1.06)
<0.001
 Pulmonary circulation disorders
1.13 (1.09-1.17)
<0.001
 Diabetes, uncomplicated
1.04 (1.03-1.05)
<0.001
 Obesity
0.97 (0.96-0.99)
<0.001
 Depression
1.08 (1.07-1.10)
<0.001
 Psychoses
1.08 (1.06-1.10)
<0.001
 Drug abuse
1.18 (1.15-1.21)
<0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department CI confidence interval.
Bold results are statistically significant.

COPD 30-day ED revisits, hospitalizations, and near-fatal events

Table 5 summarizes clinical outcomes at the visit-level. Overall, 12.3% (95% CI, 12.1%-12.4%) of ED visits for AECOPD were 30-day revisit events. Patients with a higher frequency of ED visits were more likely to develop a 30-day ED revisit (Table 5), regardless of state (all P < 0.001; Table 6).
Table 5
Outcomes of patients with Chronic Obstructive Pulmonary Disease (COPD), according to the number of COPD-related emergency department visits in one year
Variables
1 ED visit
2 ED visits
≥ 3 ED visits
P value
Number of ED visits for COPD, no.
69,398
34,010
51,328
30-day ED revisit rate for COPD, % (95% CI)*
10.5 (10.1-10.8)
30.0 (29.6-30.4)
<0.001
Hospitalization rate for COPD, % (95% CI)
62.3 (62.0-62.7)
64.9 (64.4-65.4)
62.1 (61.6-62.5)
<0.001
Near-fatal event rate, % (95% CI)
5.8 (5.6-6.0)
8.2 (7.9-8.5)
8.8 (8.6-9.1)
<0.001
Abbreviations: COPD chronic obstructive pulmonary disease ED emergency department, IQR interquartile range, CI confidence interval.
*Excluding the index ED visits and hospitalizations.
Table 6
Outcomes of chronic obstructive pulmonary disease patients, according to the number of emergency department visits, stratified by state
Variables
1 ED visit
2 ED visits
≥ 3 ED visits
P value
California
    
 Number of ED visits for COPD, no.
33,741
16,594
26,100
 30-day ED revisit rate for COPD, % (95% CI)*
11.1 (10.6-11.6)
31.7 (31.2-32.3)
<0.001
 Hospitalization rate for COPD, % (95% CI)
55.7 (55.2-56.2)
54.6 (53.9-55.4)
54.5 (53.9-55.1)
<0.001
 Near-fatal event rate, % (95% CI)
6.8 (6.5-7.1)
9.2 (8.7-9.6)
9.6 (9.2-9.9)
<0.001
Florida
    
 Number of ED visits for COPD, no.
35,657
17,416
25,228
 30-day ED revisit rate for COPD, % (95% CI)*
9.8 (9.4-10.3)
28.2 (27.6-28.8)
<0.001
 Hospitalization rate for COPD, % (95% CI)
68.6 (68.1-69.0)
71.7 (71.0-72.3)
69.9 (69.3-70.4)
<0.001
 Near-fatal event rate, % (95% CI)
4.9 (4.7-5.1)
7.3 (6.9-7.7)
9.9 (9.5-10.3)
<0.001
Nebraska
    
 Number of ED visits for COPD, no.
2009
1060
1301
 
 30-day ED revisit rate for COPD, % (95% CI)*
8.6 (7.0-10.4)
27.2 (24.8-29.7)
<0.001
 Hospitalization rate for COPD, % (95% CI)
52.5 (50.3-54.7)
56.6 (53.6-59.6)
53.0 (50.2-55.7)
0.08
 Near-fatal event rate, % (95% CI)
6.9 (5.8-8.1)
7.9 (6.4-9.7)
11.2 (9.6-13.1)
<0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, IQR interquartile range CI confidence interval.
*Excluding the index ED visits and hospitalizations.
Overall, approximately two-thirds of ED visits (62.8%; 95% CI, 62.6%-63.0%) resulted in a hospitalization. Hospitalization rates were greater than 60% across the ED frequency groups and highest with the patients with two ED visits (Table 5). Patients with frequent ED visits accounted for 55.5% (95% CI, 55.2%-55.8%) of total hospitalizations for AECOPD.
Additionally, 7.3% (95% CI, 7.2%-7.5%) of ED visits led to a near-fatal event. Patients with a higher frequency of ED visits had a higher chance of near-fatal event during the 1-year period, regardless of state (all P < 0.001; Tables 5 and 6). Patients with frequent ED visits accounted for 64.4% (95% CI, 63.5%-65.3%) of near-fatal events.

Hospital charges for AECOPD in Florida

The total charges for ED and inpatient services for AECOPD were $1.94 billion (95% CI, $1.90-1.97 billion) in Florida. Patients with frequent ED visits accounted for the majority of total charges ($1.07 billion; 95% CI, $1.04-1.09 billion); this was driven by a significant linear association between number of ED visits and charges per patient (P < 0.001; Figure 3). In addition, recurrent visits after the index ED visits accounted for 37.1% of total charges ($719 million; 95% CI, $709-731 million).

Discussion

Our study of 98,280 COPD patients showed that 29% of the patients had frequent ED visits for AECOPD (2 or more ED visits in a year). The societal burden of this population with COPD – as measured by ED visits, hospitalizations, and near-fatal events – was large. Indeed, this high-risk population accounted for 55% of all ED visits, 56% of all COPD hospitalizations, 64% of near-fatal events, all contributing to substantial healthcare spending. We also found that male sex, non-Hispanic white and black race, and lower socioeconomic status were significantly associated with a higher frequency of ED visits. These findings inform potential strategies to reduce the large public health burden from AECOPD.

Proportion of frequent ED visits for AECOPD

To date, most clinical research on patients with AECOPD has focused on predicting and preventing acute relapse and 30-day readmission [2224]. However, the predictors of acute relapse are not necessarily the predictors of frequent ED visits over longer periods. Conceptually, relapse is more likely to be associated with acute or medical factors, such as severity of exacerbation and quality of care at the index ED visit or hospitalization [24]. In contrast to acute relapse, recurrent ED visits for AECOPD over the course of a longer period of time, such as 1 year in our study, have a broader meaning because it may reflect a failure of less costly and more prevention-oriented COPD care.
A multicenter ED-based study in the early 2000s found that 64% of ED patients with AECOPD self-reported frequent ED visits within past year [11]. By contrast, a claims data study from North Carolina found that 28% of ED patients with AECOPD had frequent ED visits in the late 2000s [10]. Between 2010 and 2011, we demonstrated that 29% of ED patients with AECOPD had frequent ED visits in the two large, geographically-dispersed states, with a comparable percentage in a third state.
The reasons for the differences in the proportion of frequent ED visits for AECOPD among the studies are unclear and likely multifactorial. The population of the earlier multicenter study was limited to urban teaching hospitals that might have disproportionately high COPD morbidity, and thereby led to more frequent ED visits. Alternatively, the observed lower proportion of frequent ED visits might reflect declines in the rate of severe AECOPD over the past decade [1, 25]. Secular changes in multiple factors might have contributed to such a potential improvement, including favorable changes in personal health behavior (e.g., smoking), self-management education, access to longitudinal care, hospital-at-home care, and dissemination of evidence-based therapy. For example, the release of Global Initiatives for Chronic Obstructive Lung Disease guidelines in 2001, 2006, and 2011 may have helped reduce the rate of AECOPD [26]. Indeed, after the publication of the first guidelines, researchers reported increases in the use of long-acting beta-agonists with corticosteroids [27] and influenza vaccinations [28] as well as reductions in smoking rate [29]. However, although COPD care has improved, the use of recommended medication combinations and stage-appropriate treatment still has ample room for improvement [30]. The observed lower proportion of frequent ED visits for AECOPD in 2010–2011 supports cautious optimism that COPD morbidity can be prevented and the societal burden reduced. Yet, considering the previous knowledge that only half of patients with AECOPD seek care in the ED or outpatient clinics [31], the large remaining burden underscores the need for continued secondary prevention efforts among patients with COPD.

Characteristics of patients with frequent ED visits for AECOPD

We were also struck by the disproportionate socioeconomic disparity in frequency of ED visits for AECOPD. In the present study, we found that adults at highest risk of frequent ED visits were more likely to have public insurance, and to have lower socioeconomic status. These results support prior reports of higher rates of frequent ED visits for COPD among these vulnerable populations [10, 11]. Although the precise role of lower socioeconomic status to this disparity in COPD healthcare utilizations is unclear [5], the asthma literature would suggest that differences in health beliefs, less self-management education, and limited access to preventive and specialist care in this population might lead to a heavier reliance on episodic symptom treatment and emergency care [32]. Other potential factors that might explain the difference in ED use across socioeconomic status include degree of past and current smoking, living conditions, outpatient treatment, and COPD-specific disease severity [5, 33]. The pathway through which socioeconomic status affects healthcare utilization is undoubtedly complex; further investigation is warranted to better understand the underlying reasons for this disparity in ED utilization among patients with AECOPD.

Burden of patients with frequent ED visits for AECOPD

Consistent with the previous study from North Carolina [10], we observed substantial patient morbidity, as measured by ED visits and hospitalizations for AECOPD. Additionally, our study extended prior research by documenting relatively high use of intensive care resources and high healthcare spending in frequent ED users with AECOPD. Indeed, patients with frequent ED visits accounted for only 29% of all patients; however, they comprised 64% of mechanical ventilation use and 55% of the total charges for ED and inpatient services.
COPD is designated as an ambulatory care sensitive condition by the AHRQ, among other conditions [34]; ED visits for AECOPD can often be prevented by evidence-based outpatient care (e.g., smoking cessation, influenza and pneumococcal vaccines, knowledge of current therapy including inhaler technique, and evidence-based pharmacologic treatment) [5]. Therefore, organized efforts to develop and implement systems of care are imperative to lower COPD adverse outcomes and healthcare expenditures. If recurrent ED visits could be prevented in this study, there would have been approximately 56,456 prevented ED visits and 35,520 prevented hospitalizations in these two states alone. In terms of cost, this would have saved 719 million dollars in Florida alone.
Although these administrative data are unable to explore more granular aspects of COPD care, our findings can better inform a system of care for patients with AECOPD. At the individual patient level, the use of patient characteristics to identify patients at high-risk for frequent AECOPD remains limited [35]. The present findings underscore the importance of translating high-quality research into the risk stratification, coupled with dissemination of these finding to improve care for patients with COPD. At the health system level, our observation should facilitate further work on how to reduce the enormous and uneven public heath burden by targeting the population at greatest risk for integrated research, health policy, and community action.

Potential limitations

Our study should be viewed in the context of several potential limitations. Our data were not derived from a sample of the national COPD population. However, the data from two geographically diverse states included all ED visits and hospitalizations for approximately 19% of the US population [36]; the age and sex distributions of the ED visits mirrored a national surveillance of COPD-related ED visits [1]. Moreover, our findings persisted across the two geographically dispersed states, with the comparable findings in a third state, suggesting a potential generalizability at the nation-level. Secondly, as with any studies using administrative data, there may be some misclassification of medical claims. However, HCUP data are highly accurate, rigorously tested, and widely used to estimate diagnoses and visit frequency [37, 38]. Thirdly, our data do not include information on outpatient treatment and COPD-specific disease severity measures. As a surrogate for severity for COPD, we controlled for Elixhauser comorbidity measures in our analysis. In addition, our study did not examine care coordination, such as early discharge to pulmonary rehabilitation, or nurse or self-management education [39, 40]. Fourthly, some of the unadjusted comparisons of patient characteristics were statistically significant with a marginal clinical significance because of the large numbers. Lastly, our objective was to assess COPD-related ED visits and associated healthcare utilization. Some patients may have had visits to urgent care or other ambulatory care sites; this would have led to an underestimation of healthcare utilization for AECOPD. However, because we focused on the characteristics and burden of the frequent ED utilizers for COPD, our observations are of direct relevance to the development of strategies to improve COPD care in this important patient population.

Conclusions

By using large all-payer databases from two geographically dispersed states in US, we found that 29% of the ED patients with AECOPD had frequent ED visits and that lower socioeconomic status were significantly associated with a higher frequency of ED visits. This population accounts for the majority of all COPD-related ED visits, hospitalizations, near-fatal events, and hospital charges, and present an important public health challenge. Our observations provide a strong foundation for clinicians and researchers to evaluate specific phenotypes of COPD (e.g., frequent ED users) and to develop targeted preventive interventions. For policy makers, our findings underscore the importance of integrated strategies aimed at reducing COPD-related healthcare utilizations in an already-stressed healthcare system.

Funding support

Dr. Hasegawa was supported, in part, by Eleanor and Miles Shore Fellowship Program (Boston, MA). Dr. Tsugawa was supported, in part, by Honjo International Scholarship Foundation (Tokyo, Japan). The funding organizations had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review, or approval of the manuscript.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

Dr. Camargo has provided consultation for AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer, and received research grants from AstraZeneca and Novartis. The other authors have no financial relationships relevant to this article to disclose.

Authors’ contributions

Conception and design: KH, YT, and CC; Analysis and interpretation: KH, YT, CT, DB, and CC; Drafting the manuscript for important intellectual content: KH, YT, CT, DB, and CC. All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH: Chronic obstructive pulmonary disease surveillance-United States, 1999–2011. Chest. 2013, 144: 284-305. 10.1378/chest.13-0809.PubMedPubMedCentralCrossRef Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH: Chronic obstructive pulmonary disease surveillance-United States, 1999–2011. Chest. 2013, 144: 284-305. 10.1378/chest.13-0809.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Kanner RE, Anthonisen NR, Connett JE, Group LHSR: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001, 164: 358-364. 10.1164/ajrccm.164.3.2010017.PubMedCrossRef Kanner RE, Anthonisen NR, Connett JE, Group LHSR: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001, 164: 358-364. 10.1164/ajrccm.164.3.2010017.PubMedCrossRef
3.
Zurück zum Zitat Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57: 847-852. 10.1136/thorax.57.10.847.PubMedPubMedCentralCrossRef Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57: 847-852. 10.1136/thorax.57.10.847.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157: 1418-1422. 10.1164/ajrccm.157.5.9709032.PubMedCrossRef Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157: 1418-1422. 10.1164/ajrccm.157.5.9709032.PubMedCrossRef
5.
6.
Zurück zum Zitat Strassels SA, Smith DH, Sullivan SD, Mahajan PS: The costs of treating COPD in the United States. Chest. 2001, 119: 344-352. 10.1378/chest.119.2.344.PubMedCrossRef Strassels SA, Smith DH, Sullivan SD, Mahajan PS: The costs of treating COPD in the United States. Chest. 2001, 119: 344-352. 10.1378/chest.119.2.344.PubMedCrossRef
8.
Zurück zum Zitat Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.PubMedCrossRef Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.PubMedCrossRef
9.
Zurück zum Zitat Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ, Investigators CO: The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011, 140: 626-633. 10.1378/chest.10-2948.PubMedPubMedCentralCrossRef Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ, Investigators CO: The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011, 140: 626-633. 10.1378/chest.10-2948.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Yeatts KB, Lippmann SJ, Waller AE, Lich KH, Travers D, Weinberger M, Donohue JF: Population-based Burden of COPD-related Visits in the Emergency Department (ED): Return ED Visits, Hospital Admissions, and Comorbidity Risks. Chest. 2013, 144: 784-793. 10.1378/chest.12-1899.PubMedCrossRef Yeatts KB, Lippmann SJ, Waller AE, Lich KH, Travers D, Weinberger M, Donohue JF: Population-based Burden of COPD-related Visits in the Emergency Department (ED): Return ED Visits, Hospital Admissions, and Comorbidity Risks. Chest. 2013, 144: 784-793. 10.1378/chest.12-1899.PubMedCrossRef
11.
Zurück zum Zitat Tsai CL, Griswold SK, Clark S, Camargo CA: Factors associated with frequency of emergency department visits for chronic obstructive pulmonary disease exacerbation. J Gen Intern Med. 2007, 22: 799-804. 10.1007/s11606-007-0191-7.PubMedPubMedCentralCrossRef Tsai CL, Griswold SK, Clark S, Camargo CA: Factors associated with frequency of emergency department visits for chronic obstructive pulmonary disease exacerbation. J Gen Intern Med. 2007, 22: 799-804. 10.1007/s11606-007-0191-7.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36: 8-27. 10.1097/00005650-199801000-00004.PubMedCrossRef Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36: 8-27. 10.1097/00005650-199801000-00004.PubMedCrossRef
17.
Zurück zum Zitat Hasegawa K, Brown DF, Tsugawa Y, Camargo CA: Epidemiology of emergency department visits for opioid overdose: a population-based study. Mayo Clin Proc. 2014, 89 (4): 462-471. 10.1016/j.mayocp.2013.12.008.PubMedCrossRef Hasegawa K, Brown DF, Tsugawa Y, Camargo CA: Epidemiology of emergency department visits for opioid overdose: a population-based study. Mayo Clin Proc. 2014, 89 (4): 462-471. 10.1016/j.mayocp.2013.12.008.PubMedCrossRef
19.
Zurück zum Zitat McCullagh P, Nelder JA: Generalized Linear Models (Monographs on statistics and applied probability 37). 1989, London: Chapman Hall McCullagh P, Nelder JA: Generalized Linear Models (Monographs on statistics and applied probability 37). 1989, London: Chapman Hall
21.
Zurück zum Zitat Tsai CL: Appropriate statistical treatment of frequent emergency department visits in health services research. Ann Emerg Med. 2007, 49: 385-PubMedCrossRef Tsai CL: Appropriate statistical treatment of frequent emergency department visits in health services research. Ann Emerg Med. 2007, 49: 385-PubMedCrossRef
23.
Zurück zum Zitat Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS: Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010, 170: 1664-1670.PubMedPubMedCentral Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS: Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010, 170: 1664-1670.PubMedPubMedCentral
24.
Zurück zum Zitat Kim S, Emerman CL, Cydulka RK, Rowe BH, Clark S, Camargo CA, Investigators M: Prospective multicenter study of relapse following emergency department treatment of COPD exacerbation. Chest. 2004, 125: 473-481. 10.1378/chest.125.2.473.PubMedCrossRef Kim S, Emerman CL, Cydulka RK, Rowe BH, Clark S, Camargo CA, Investigators M: Prospective multicenter study of relapse following emergency department treatment of COPD exacerbation. Chest. 2004, 125: 473-481. 10.1378/chest.125.2.473.PubMedCrossRef
25.
Zurück zum Zitat Baillargeon J, Wang Y, Kuo YF, Holmes HM, Sharma G: Temporal trends in hospitalization rates for older adults with chronic obstructive pulmonary disease. Am J Med. 2013, 126: 607-614. 10.1016/j.amjmed.2013.01.035.PubMedCrossRef Baillargeon J, Wang Y, Kuo YF, Holmes HM, Sharma G: Temporal trends in hospitalization rates for older adults with chronic obstructive pulmonary disease. Am J Med. 2013, 126: 607-614. 10.1016/j.amjmed.2013.01.035.PubMedCrossRef
26.
Zurück zum Zitat Rabe KF, Wedzicha JA: Controversies in treatment of chronic obstructive pulmonary disease. Lancet. 2011, 378: 1038-1047. 10.1016/S0140-6736(11)61295-6.PubMedCrossRef Rabe KF, Wedzicha JA: Controversies in treatment of chronic obstructive pulmonary disease. Lancet. 2011, 378: 1038-1047. 10.1016/S0140-6736(11)61295-6.PubMedCrossRef
27.
Zurück zum Zitat Chiu S, Kelton C, Guo J, Wigle P, Lin A, Szeinbach S: Utilization, spending, and price trends for long-acting beta agonists and inhaled corticosteroids in the US Medicaid program from 1991 to 2010. Am Health Drug Benefits. 2011, 4: 140-149.PubMedPubMedCentral Chiu S, Kelton C, Guo J, Wigle P, Lin A, Szeinbach S: Utilization, spending, and price trends for long-acting beta agonists and inhaled corticosteroids in the US Medicaid program from 1991 to 2010. Am Health Drug Benefits. 2011, 4: 140-149.PubMedPubMedCentral
28.
Zurück zum Zitat Setse RW, Euler GL, Gonzalez-Feliciano AG, Bryan LN, Furlow C, Weinbaum CM, Singleton JA: Influenza Vaccination Coverage—United States, 2000–2010. MMWR Surveill Summ. 2011, 60: 38-41.PubMed Setse RW, Euler GL, Gonzalez-Feliciano AG, Bryan LN, Furlow C, Weinbaum CM, Singleton JA: Influenza Vaccination Coverage—United States, 2000–2010. MMWR Surveill Summ. 2011, 60: 38-41.PubMed
29.
Zurück zum Zitat Centers for Disease Control and Prevention: Trends in Current Cigarette Smoking Among high Hschool Students and Adults, United States, 1965--2010. 2011, Atlanta, GA: US Department of Health and Human Services; 2011 Centers for Disease Control and Prevention: Trends in Current Cigarette Smoking Among high Hschool Students and Adults, United States, 1965--2010. 2011, Atlanta, GA: US Department of Health and Human Services; 2011
30.
Zurück zum Zitat Chavez PC, Shokar NK: Diagnosis and management of chronic obstructive pulmonary disease (COPD) in a primary care clinic. COPD. 2009, 6: 446-451. 10.3109/15412550903341455.PubMedCrossRef Chavez PC, Shokar NK: Diagnosis and management of chronic obstructive pulmonary disease (COPD) in a primary care clinic. COPD. 2009, 6: 446-451. 10.3109/15412550903341455.PubMedCrossRef
32.
Zurück zum Zitat Canino G, McQuaid EL, Rand CS: Addressing asthma health disparities: a multilevel challenge. J Allergy Clin Immunol. 2009, 123: 1209-1217. 10.1016/j.jaci.2009.02.043. quiz 1218–1209PubMedPubMedCentralCrossRef Canino G, McQuaid EL, Rand CS: Addressing asthma health disparities: a multilevel challenge. J Allergy Clin Immunol. 2009, 123: 1209-1217. 10.1016/j.jaci.2009.02.043. quiz 1218–1209PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Lange P, Marott JL, Vestbo J, Ingebrigtsen TS, Nordestgaard BG: Socioeconomic Status and Prognosis of COPD in Denmark. COPD. 2014, [Epub ahead of print] Lange P, Marott JL, Vestbo J, Ingebrigtsen TS, Nordestgaard BG: Socioeconomic Status and Prognosis of COPD in Denmark. COPD. 2014, [Epub ahead of print]
35.
Zurück zum Zitat Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010, 182: 598-604. 10.1164/rccm.200912-1843CC.PubMedCrossRef Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010, 182: 598-604. 10.1164/rccm.200912-1843CC.PubMedCrossRef
37.
Zurück zum Zitat Basu J, Mobley LR: Do HMOs reduce preventable hospitalizations for Medicare beneficiaries?. Med Care Res Rev. 2007, 64: 544-567. 10.1177/1077558707301955.PubMedCrossRef Basu J, Mobley LR: Do HMOs reduce preventable hospitalizations for Medicare beneficiaries?. Med Care Res Rev. 2007, 64: 544-567. 10.1177/1077558707301955.PubMedCrossRef
38.
Zurück zum Zitat Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA: Temporal trends in emergency department visits for bronchiolitis in the United States, 2006–2010. Pediatr Infect Dis J. 2014, 33: 11-18. 10.1097/INF.0b013e3182a5f324.PubMedPubMedCentralCrossRef Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA: Temporal trends in emergency department visits for bronchiolitis in the United States, 2006–2010. Pediatr Infect Dis J. 2014, 33: 11-18. 10.1097/INF.0b013e3182a5f324.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Effing T, Monninkhof EM, van der Valk PD, van der Palen J, van Herwaarden CL, Partidge MR, Walters EH, Zielhuis GA: Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007, CD002990-4 Effing T, Monninkhof EM, van der Valk PD, van der Palen J, van Herwaarden CL, Partidge MR, Walters EH, Zielhuis GA: Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007, CD002990-4
40.
Zurück zum Zitat O’Malley AS, Pham HH, Schrag D, Wu B, Bach PB: Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics. Med Care. 2007, 45: 562-570. 10.1097/MLR.0b013e3180408df8.PubMedCrossRef O’Malley AS, Pham HH, Schrag D, Wu B, Bach PB: Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics. Med Care. 2007, 45: 562-570. 10.1097/MLR.0b013e3180408df8.PubMedCrossRef
Metadaten
Titel
Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease
verfasst von
Kohei Hasegawa
Yusuke Tsugawa
Chu-Lin Tsai
David FM Brown
Carlos A Camargo Jr
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
Respiratory Research / Ausgabe 1/2014
Elektronische ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-15-40

Weitere Artikel der Ausgabe 1/2014

Respiratory Research 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.